Regeneron Pharmaceuticals (REGN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$902.90-2.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · REGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 5.9% |
| Our one-year growth estimate | diamond | 16.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 10.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
REGN — CEO transition
Dated 2026-09-30
CEO — Leonard S. Schleifer, M.D., Ph.D.: The filing discloses new equity compensation awards for the CEO and CSO, not a change in management personnel or roles.
Why it matters: EYLEA HD sales are rising, but older EYLEA sales are falling. Total U.S. sales show whether HD growth can offset that drop.
Watch forQ4 U.S. EYLEA HD sales grow year over year, and combined EYLEA HD plus EYLEA sales exceed $1.099 billion.
Also watch forQ4 U.S. EYLEA HD sales fall year over year, or combined sales fall below $1.099 billion.
Why it matters: Early results showed a large drop in liver fat after one dose. A Phase 3 start would move this program toward a larger test.
Supportive ifRegeneron starts the planned Phase 3 MASH or MASLD study in Q4 2026.
Worry ifThe company says the Phase 3 study did not start by year-end 2026, or pauses or cancels it.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$106 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $307 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,596 loss on $10,000 · 26.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.